Latest research on MK-0518

Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval. [Wikipedia]

Latest findings

Since the late 1990s, several different chemical scaffolds have been studied for their ability to inhibit HIV-1 integration [3], [4], leading to the approval of the first HIV-1 integrase strand transfer inhibitor (INSTI) for the treatment of HIV-1 infection in 2007 (raltegravir, RAL, MK-0518, Isentress, Merck Research Laboratories) [5]. [source, 2013]
HIV-1 integrase inhibitors currently in the clinic include the approved drugs raltegravir (RAL; MK-0518) [15], [16] and elvitegravir (EVG; GS-9137) [17], [18], and the newer representative dolutegravir (DTG; S/GSK1349572), which is currently in late-stage clinical development [19], [20]. [source, 2013]
Raltegravir (brand name Isentress and formerly known as MK-0518) was developed by Merck and approved by the US Food and Drug Administration (FDA) in 2007 in combination with other ARV agents for treatment of adults infected with HIV. [source, 2013]
Other studies, such as Blocking integrase in treatment Experienced patients with a Novel Compound against HIV: MeRcK, MK-0518 (NCT00293267 and NCT00293254)(BENCHMRK), Once Daily Isentress (NCT00941083)(ODIS) and MK-0518 protocol 071, (NCT00745823)(QDMRK), have been conducted and concluded that raltegravir (400 mg twice daily) was generally well tolerated and had potent ARV activity8,12–14 [source, 2013]
aDrugs with sales above $100 million in 2010: Atripla ($2927 million), Truvada ($2746 million), Reyataz ($1479 million), Kaletra ($1255 million), Isentress ($1090 million), Prezista ($888 million), Epzicom ($858 million), Combivir ($561 million), Norvir ($344 million), Sustiva ($315 million), Viramune ($295 million), Intelence ($243 million), Trizivir ($223 million), Crixivan ($206 million), Epivir ($178 million), Ziagen ($159 million), Selzentry ($124 million), Viracept ($112 million); values from EvaluatePharma [23]. [source, 2013]
In September she started antiretroviral therapy (ART): Lopinavir/Ritonavir cp 200/50 mg (2cp × 2/day) and raltegravir (Isentress) cp 400 mg (1 cp × 2/day). [source, 2012]
Thus, Merck and Co has recently developed the raltegravir (RAL, MK-0518), a potent INSTI (IN ST Inhibitor) that derives from DKAs (Diketo Acids) and which is now widely used in AIDS therapy [8], [9]. [source, 2012]
Raltegravir (MK-0518) was obtained from Bio-Connect services [35] and used at a final concentration of 1 nM. [source, 2012]
This trench was subsequently exploited in the design of Isentress (raltegravir), an HIV drug approved by the FDA in 2007 (42). [source, 2011]
Food and Drug Administration (FDA) approved the first integration inhibitor, Isentress TM drug, also known as raltegravir (MK-0518), an anti-AIDS agent [11]. [source, 2011]